Half-Year Figures: ZEISS Looks back on Good First Six Months Overall

Half-year revenue reaches 3.2 billion euros (+6% compared to prior year) – EBIT at 455 million euros (+12 million euros compared to prior year)

Oberkochen, Germany | 19 May 2020 | ZEISS Group

  • The Semiconductor Manufacturing Technology and Medical Technology segments contributed in particular to growth in the first six months
  • Initial impact of the COVID-19 pandemic felt particularly in Q2
  • ZEISS portfolio ensures stability even during the COVID-19 pandemic
  • Difficult to form outlook on further progression of fiscal year
  • ZEISS CEO Lamprecht: "Overall, we were successful during the first half of the fiscal year. However, the COVID-19 pandemic has had a major impact on the global economy – including on ZEISS' lines of business. ZEISS' resilience measures will help it combat the current challenges in the best possible way.”
Press Contact

Jörg Nitschke
Group Spokesman
Phone: +49 7364 20-3242
joerg .nitschke @zeiss .com

Overall, the first six months of fiscal year 2019/20 (ended 31 March 2020) went well for the ZEISS Group. It saw its revenue rise by 6 percent (compared to 3 percent) to EUR 3.213 billion (first six months of 2018/19: EUR 3.019 billion). 90 percent of this sum was generated by markets outside Germany. At EUR 455 million, earnings before interest and tax (EBIT) were slightly higher than the previous year (EUR 443 million). The EBIT margin was at 14.2%. Incoming orders hit EUR 3.601 billion (1st six months of 2018/19: EUR 3.161 billion).

"Overall, we were successful during the first half of the fiscal year. However, the COVID-19 pandemic has had a major impact on the global economy – including on ZEISS' lines of business, " said Dr. Karl Lamprecht, ZEISS President and CEO. He continued: "ZEISS' resilience measures will help it combat the current challenges in the best possible way. "

Segment development

Revenue (in EUR million)


1st six months
of 2019/20

1st six months
of 2018/19

Change (like-for-like)

Semiconductor Manufacturing Technology



+18 % (+17 %)

Industrial Quality & Research



+5% (-7 %)

Medical Technology



+4 % (+3 %)

Consumer Markets



-3 % (-3 %)

In the first half of the year, the four segments of the ZEISS Group developed according to different dynamics. The Semiconductor Manufacturing Technology segment was able to continue expanding, thanks in particular to the high demand for extreme ultraviolet (EUV) lithography systems, a technology that is still in the launch phase, and continues to focus on deep ultraviolet (DUV) lithography systems.
In the Industrial Quality & Research segment, the Industrial Quality Solutions area felt the effects of the COVID-19 pandemic due to weak development in the automobile industry. In the past fiscal year ZEISS acquired GOM (Brunswick, Germany), a leading supplier of hardware and software for optical 3D coordinate metrology. This enabled ZEISS to generate further growth potential in surface measurement and digitalization. The business at Research Microscopy Solutions grew overall. Researchers worldwide looking into the coronavirus (SARS-CoV-2) are relying even more on the ZEISS Celldiscoverer 7, an automated light microscope.

While the Medical Technology segment achieved a lower growth dynamic than in the previous year due to the impact of the COVID-19 pandemic, the segment successfully expanded its market position through its innovative systems for neurosurgery and ophthalmology.
The Consumer Markets segment was the most affected by the COVID-19 pandemic. The Vision Care area saw growth in the first six months of the fiscal year and the expansion of its market position in the eyeglass lens market. Nevertheless, the impact of the COVID-19 pandemic resulted in a sharp decline in sales across all regions when the lockdown came into effect.

Key figures

Free cash flow amounted to EUR 180 million (1st half of 2018/19: EUR 341 million). With a total of EUR 4,179 million, the company's equity rose by 5 percent to the end-of-year figure for fiscal year 2018/19 (30 September 2019: EUR 3,990 million).

ZEISS expenditure on research and development totaled around 12 percent of revenue. This amounted to EUR 398 million in the first half of fiscal year 2019/20 (1st half of 2018/19: EUR 322 million).
Investments in property, plant and equipment amounted to EUR 215 million in the reporting period (1st half of 2018/19: EUR 133 million) as compared to depreciations totaling EUR 123 million (1st half of 2018/19: EUR 105 million).

Net liquidity totaled 1,362 million euros on 31 March 2020.

The COVID-19 pandemic led to a downturn in revenue, particularly in the EMEA and APAC regions. Conversely, the Americas region saw slight growth in revenue. China saw a renewed upward trend in March.

"Our global investment strategy involves investments in innovations and digitalization in particular, but also in the further expansion of our modern infrastructure. It lays the groundwork for the ZEISS Group to continue growing," says Dr. Christian Müller, Chief Financial Officer of the Carl Zeiss AG. Lamprecht added: "Our investment strategy is supplemented by the acquisition of highly innovative companies that will allow them to unlock their full potential in our portfolio, and thus form a key part of the ZEISS future strategy."

ZEISS' acquisitions during the first six months of the year include the acquisition of software firm Saxonia Systems AG. The company has been operating under the name Carl Zeiss Digital Innovation since March 2020. With this acquisition, ZEISS is systematically expanding its software know-how and securing the expertise and resources of Saxonia Systems to realize digital projects of strategic significance.

At the end of the first six months of the year (31 March 2020), ZEISS had a global workforce of 31,906 employees. Its headcount thus increased by 5 percent as compared to 31 March 2019.

Impact of the COVID-19 pandemic on ZEISS

While the Semiconductor Manufacturing Technology segment continues to see very stable developments, the other segments have certainly been affected by the global economic impact of the COVID-19 pandemic.

A central task force was formed early on and is responsible for coordinating all the required measures in close collaboration with local and area-specific units. ZEISS is pursuing four aims to limit the impact of the crisis: To protect its employees' health and safety, ensure smart business continuity as best as possible and support its customers worldwide. At the same time, the company will be demonstrating its resilience in combating the economic impact of the pandemic on the company in the best possible way. In addition to these three urgent goals, ZEISS shall be guided by a further aim that goes beyond the current crisis: that of better leveraging the market opportunities and strategic options, as they arise from the current changes.


Many predict that the COVID-19 pandemic will result in considerable challenges for the global economy.
ZEISS is now also feeling the impact of the COVID-19 crisis and a decline in its business – to differing extents at the regional and segment levels. However, thanks to a package of measures launched early on, ZEISS has been able to navigate its way through the COVID-19 crisis. ZEISS is now consistently pursuing this program of measures.

At this time it is not possible to make a reliable prediction for the 2019/20 fiscal year due to the global uncertainty surrounding the COVID-19 pandemic. However, a decline in revenue and EBIT is to be expected during the second half of the fiscal year.

"This is the time for stability – particularly with regard to providing our customers with the best possible service. The impact of the COVID-19 pandemic requires a high level of flexibility and a concerted effort from all employees," says Lamprecht. "Moreover, we are already thinking about life after the COVID-19 pandemic so that we, as an innovative company, can better leverage the opportunities to emerge from this situation even stronger." Since launching its comprehensive packages of measures to combat the COVID-19 crisis, ZEISS believes it is stable and well-structured due to its portfolio – which is aligned with megatrends – as well as its strong market position, international setup and strategic investment for the future.


ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling more than 6.4 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (status: 30 September 2019).

For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.

With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership.

With over 31,000 employees, ZEISS is active globally in almost 50 countries with around 60 sales and service companies, 30 production sites and 25 development sites. Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.

Further information at www.zeiss.com

Press Contact

Jörg Nitschke
Group Spokesman
Phone: +49 7364 20-3242
joerg .nitschke @zeiss .com

Further Articles

ZEISS Becomes Founding Member of Deutsches Museum

To mark its 175th anniversary, ZEISS has donated five million euros to the future initiative for modernizing the Deutsches Museum in Munich.

ZEISS has donated five million euros to the future initiative for modernizing the Deutsches Museum in Munich. The clo...

Jul 8, 2021

ZEISS Symposium 2021: Optical Technologies Drive Medical Innovation

At this year's ZEISS Symposium "Optics in the Medical World" scientists and experts in the field discussed innovative technologies in medicine.

At the virtual Symposium, some 300 international experts discussed the role and the potential of optical technologies...

Jun 10, 2021

ZEISS Innovation Hub in Dresden Opens Its Doors

Team has moved into the building of the EKFZ on the campus of the University Hospital

ZEISS and the Dresden University of Technology are using the ZEISS Innovation Hub in Dresden to further expand their ...

Jun 9, 2021